Citations (16)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Russell Lewis, Jan Philipp Bewersdorf & Amer M Zeidan. (2021) Clinical Management of Anemia in Patients with Myelodysplastic Syndromes: An Update on Emerging Therapeutic Options. Cancer Management and Research 13, pages 645-657.
Read now
Read now
Nora Chokr, Alexander B. Pine, Jan Philipp Bewersdorf, Rory M. Shallis, Maximilian Stahl & Amer M. Zeidan. (2019) Getting personal with myelodysplastic syndromes: is now the right time?. Expert Review of Hematology 12:4, pages 215-224.
Read now
Read now
Amer M. Zeidan, Maximilian Stahl & Rami Komrokji. (2016) Emerging biological therapies for the treatment of myelodysplastic syndromes. Expert Opinion on Emerging Drugs 21:3, pages 283-300.
Read now
Read now
Abdallah Abou Zahr, Ehab Saad Aldin, Lisa Barbarotta, Nikolai Podoltsev & Amer M Zeidan. (2015) The clinical use of DNA methyltransferase inhibitors in myelodysplastic syndromes. Expert Review of Anticancer Therapy 15:9, pages 1019-1036.
Read now
Read now
Articles from other publishers (12)
Yu-Hung Wang, Chien-Chin Lin, Kristian Gurashi, Bettina Wingelhofer, Fabio M. R. Amaral, Chi-Yuan Yao, Hsin Ting Hsieh, Ming Chih Liu, Hsin-An Hou, Wen-Chien Chou, Kiran Batta, Daniel H. Wiseman & Hwei-Fang Tien. (2023) Higher MDMX expression was associated with hypomethylating agent resistance and inferior survival in MDS patients, inferring it a potential therapeutic target. Leukemia 37:12, pages 2507-2511.
Crossref
Crossref
Susann Winter, Saeed Shoaie, Shahram Kordasti & Uwe Platzbecker. (2020) Integrating the “Immunome” in the Stratification of Myelodysplastic Syndromes and Future Clinical Trial Design. Journal of Clinical Oncology 38:15, pages 1723-1735.
Crossref
Crossref
Anne Calleja, Seongseok Yun, Chimène Moreilhon, Jean Michel Karsenti, Lauris Gastaud, Lionel Mannone, Rami Komrokji, Najla Ali, Bérangère Dadone‐montaudie, Guillaume Robert, Patrick Auberger, Sophie Raynaud, David A. Sallman & Thomas Cluzeau. (2020) Clonal selection in therapy‐related myelodysplastic syndromes and acute myeloid leukemia under azacitidine treatment. European Journal of Haematology 104:5, pages 488-498.
Crossref
Crossref
Guillermo F. Sanz, Mariam Ibañez & Esperanza Such. (2019) Do next-generation sequencing results drive diagnostic and therapeutic decisions in MDS?. Blood Advances 3:21, pages 3454-3460.
Crossref
Crossref
Lucas H. Rifkin & Eric Y. Loo. (2019) Molecular Genetics in Myelodysplasia Outcomes Prognostication. Advances in Molecular Pathology 2:1, pages 35-43.
Crossref
Crossref
Amer M. Zeidan, Rory M. Shallis, Rong Wang, Amy Davidoff & Xiaomei Ma. (2019) Epidemiology of myelodysplastic syndromes: Why characterizing the beast is a prerequisite to taming it. Blood Reviews 34, pages 1-15.
Crossref
Crossref
Jiayu Huang, Huihui Zhao, Ming Hong, Han Zhu, Yu Zhu, Yun Lian, Shan Li, Jianyong Li & Sixuan Qian. (2018) Early recovery of the platelet count after decitabine-based induction chemotherapy is a prognostic marker of superior response in elderly patients with newly diagnosed acute myeloid leukaemia. BMC Cancer 18:1.
Crossref
Crossref
Amer M. Zeidan, Maximilian Stahl, Mikkael A. Sekeres, David P. Steensma, Rami S. Komrokji & Steven D. Gore. (2017) A call for action: Increasing enrollment of untreated patients with higher-risk myelodysplastic syndromes in first-line clinical trials. Cancer 123:19, pages 3662-3672.
Crossref
Crossref
James A. KennedyBenjamin L. Ebert. (2017) Clinical Implications of Genetic Mutations in Myelodysplastic Syndrome. Journal of Clinical Oncology 35:9, pages 968-974.
Crossref
Crossref
A M Zeidan, M A Sekeres, G Garcia-Manero, D P Steensma, K Zell, J Barnard, N A Ali, C Zimmerman, G Roboz, A DeZern, A Nazha, E Jabbour, H Kantarjian, S D Gore, J P Maciejewski, A List & R Komrokji. (2015) Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides. Leukemia 30:3, pages 649-657.
Crossref
Crossref
Amer M. Zeidan, Mikkael A. Sekeres, Xiao‐Feng Wang, Najla Al Ali, Guillermo Garcia‐Manero, David P. Steensma, Gail Roboz, John Barnard, Eric Padron, Amy DeZern, Jaroslaw P. Maciejewski, Alan F. List & Rami S. Komrokji. (2015) Comparing the prognostic value of risk stratifying models for patients with lower‐risk myelodysplastic syndromes: Is one model better?. American Journal of Hematology 90:11, pages 1036-1040.
Crossref
Crossref
Aziz NazhaMikkael A. SekeresSteven D. Gore & Amer M. Zeidan. (2015) Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?. The Oncologist 20:9, pages 1069-1076.
Crossref
Crossref